Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAYLOR
NCT07340398Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Dec 2025
- Primary completion
- Dec 2028
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab rezetecan, pyrotinib in breast cancer, sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Started Dec 2025; status: recruiting.
02
Drugs
trastuzumab rezetecanpyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07340398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07340398.